Vimta Labs is engaged in the business of testing food and drugs. It also does contract research for clinical research and pre-clinical studies.
Company was expected to give good quarter and has delivered.
VIMTA LABS: Q2 CONS NET PROFIT 97M RUPEES VS 75M (YOY); 81M (QOQ) || Q2 REVENUE 754M RUPEES VS 593M (YOY); 613M (QOQ)
DII have bought significantly in the last quarter, Some news is coming up
TARGET : See CHART
Company was expected to give good quarter and has delivered.
VIMTA LABS: Q2 CONS NET PROFIT 97M RUPEES VS 75M (YOY); 81M (QOQ) || Q2 REVENUE 754M RUPEES VS 593M (YOY); 613M (QOQ)
DII have bought significantly in the last quarter, Some news is coming up
TARGET : See CHART
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。